BIOMAT Database Logo BIOMAT Database Logo

[Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. 1985

N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann

Long-term treatment of congestive heart failure with prazosin is disputed. Only few controlled trials have been reported so far. Our study is the first randomized double-blind placebo controlled trial over several months that also takes haemodynamic measurements into account. 25 patients with congestive heart failure classes III and IV (NYHA) received either prazosin 20 mg/d orally (n = 12) or placebo (n = 13) and were followed up closely. Before treatment, after 6 and after 12 months we performed echocardiography, heart volume (estimated by chest X-ray) and right heart catheterization at rest and during exercise. No significant differences could be noticed during follow-up concerning the following parameters: symptoms (NYHA), left ventricular end-diastolic diameter, shortening fraction, heart volume and systemic vascular resistance. While diuretics could be reduced in 3 patients with placebo an increasing dose was necessary in 6 out of 12 patients of the prazosin group. Long-term treatment of congestive heart failure with prazosin may be valuable only in exceptional cases.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006350 Heart Valve Prosthesis A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material. Prosthesis, Heart Valve,Cardiac Valve Prosthesis,Cardiac Valve Prostheses,Heart Valve Prostheses,Prostheses, Cardiac Valve,Prostheses, Heart Valve,Prosthesis, Cardiac Valve,Valve Prostheses, Cardiac,Valve Prostheses, Heart,Valve Prosthesis, Cardiac,Valve Prosthesis, Heart

Related Publications

N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Long-term therapy of heart failure with prazosin: a randomized double blind trial.
February 1980, The American journal of cardiology,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Hemodynamic effects of prazosin in chronic heart failure.
September 1981, American heart journal,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
December 1983, American heart journal,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study.
March 2012, Clinical research in cardiology : official journal of the German Cardiac Society,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
[Hemodynamic effects of prazosin in chronic congestive heart failure].
June 1980, Archives des maladies du coeur et des vaisseaux,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure.
January 1981, Acta medica Scandinavica,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
[The effects of prazosin in patients with chronic refractory heart failure-acute hemodynamic effects of oral prazosin and long-term therapy (author's transl)].
May 1981, Kokyu to junkan. Respiration & circulation,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Long-term treatment of severe chronic heart failure with captopril: a double-blind, randomized, placebo-controlled, long-term study.
January 1987, Journal of cardiovascular pharmacology,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure.
January 1986, Acta medica Scandinavica,
N Reifart, and A D Schmidt-Moritz, and M Nadj, and M Kaltenbach, and W D Bussmann
[Hemodynamic effects of prazosin in heart failure].
November 1979, La Nouvelle presse medicale,
Copied contents to your clipboard!